EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Cardiac Biomarkers to Refine Pretest Probability for Coronary Obstruction and Predict Survival After Revascularization in Chronic Coronary Syndrome

Andrej Teren iD, Jeffrey Netto iD, Joachim Thiery iD, Holger Thiele iD, Christoph Stellbrink iD, Dennis Lawin iD, Thorsten Lawrenz iD, Anselm Artur Derda iD, Sylvia Henger iD, Holger Kirsten, Markus Scholz, Thorsten Kaiser iD

Journal of the American Heart Association · 02.06.2026 · 15 (11)

DOI: 10.1161/jaha.125.048737 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 02.06.2026. Verfasst von Andrej Teren und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Intensive Care Medicine Bielefeld University, Klinikum Bielefeld Mitte Bielefeld Germany. Hauptthemen laut MEDLINE: Coronary Stenosis, Myocardial Revascularization, Natriuretic Peptide, Brain, Peptide Fragments. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The diagnostic and prognostic roles of cardiovascular biomarkers in chronic coronary syndrome remain unclear.

Methods

Patients undergoing coronary angiography for suspected chronic coronary syndrome were prospectively enrolled (n=2251; median follow‐up 12.6 years). Obstructive coronary artery disease was defined as ≥50% stenosis in ≥1 major epicardial vessel. HsTnT (high‐sensitivity cardiac troponin T), NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity C‐reactive protein, interleukin‐6, and copeptin were measured. Receiver operating characteristic analysis and Cox regression with biomarker × treatment interaction testing were performed.

Results

Overall, 888 patients (39.4%) had obstructive coronary artery disease. Only hsTnT showed meaningful diagnostic capacity (area under the curve 0.669; risk factor‐weighted clinical likelihood area under the curve 0.663), with incremental benefit inversely proportional to risk factor‐weighted clinical likelihood category (Δ area under the curve: very low 10.4%, low 8.0%, intermediate/high 5.0%). NT‐proBNP was the strongest mortality predictor across optimal medical therapy (hazard ratio [HR], 1.488 [95% CI, 1.288–1.720], P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary StenosisMyocardial RevascularizationNatriuretic Peptide, BrainPeptide FragmentsTroponin TAgedFemaleHumansMaleMiddle AgedBiomarkersC-Reactive ProteinChronic DiseaseCoronary AngiographyGlycopeptidesInterleukin-6Predictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

B‐type natriuretic peptidechronic coronary syndromepretest probabilityrevascularizationtroponin

Substanzen

BiomarkersC-Reactive ProteincopeptinsGlycopeptidesIL6 protein, humanInterleukin-6Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponin T

Autor:innen und Institutionen

  • Department of Cardiology and Intensive Care Medicine Bielefeld University, Klinikum Bielefeld Mitte Bielefeld Germany.
  • Leipzig Research Centre for Civilisation Diseases (LIFE) University of Leipzig Germany.
  • Institute for Laboratory Medicine, Microbiology and Pathobiochemistry, University Hospital Ostwestfalen-Lippe (UK-OWL), Campus Klinikum Lippe Bielefeld University Bielefeld Germany.
  • Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics University Hospital Leipzig Germany.
  • Faculty of Medical Christian-Albrechts-University Kiel Germany.
  • Department of Internal Medicine/Cardiology Heart Center Leipzig at Leipzig University Leipzig Germany.

ORCID-Profile: Andrej Teren, Jeffrey Netto, Joachim Thiery, Holger Thiele, Christoph Stellbrink, Dennis Lawin, Thorsten Lawrenz, Anselm Artur Derda, Sylvia Henger, Thorsten Kaiser

Zitieren

APA

Teren, A., Netto, J., Thiery, J., Thiele, H., Stellbrink, C., Lawin, D., Lawrenz, T., Derda, A. A., Henger, S., Kirsten, H., Scholz, M., & Kaiser, T. (2026). Cardiac Biomarkers to Refine Pretest Probability for Coronary Obstruction and Predict Survival After Revascularization in Chronic Coronary Syndrome. Journal of the American Heart Association, 15(11). https://doi.org/10.1161/jaha.125.048737

Vancouver

Teren A, Netto J, Thiery J, Thiele H, Stellbrink C, Lawin D, et al. Cardiac Biomarkers to Refine Pretest Probability for Coronary Obstruction and Predict Survival After Revascularization in Chronic Coronary Syndrome. Journal of the American Heart Association. 2026;15(11). doi:10.1161/jaha.125.048737

BibTeX
@article{Teren2026,
  author = {Teren, Andrej and Netto, Jeffrey and Thiery, Joachim and Thiele, Holger and Stellbrink, Christoph and Lawin, Dennis and Lawrenz, Thorsten and Derda, Anselm Artur and Henger, Sylvia and Kirsten, Holger and Scholz, Markus and Kaiser, Thorsten},
  title = {Cardiac Biomarkers to Refine Pretest Probability for Coronary Obstruction and Predict Survival After Revascularization in Chronic Coronary Syndrome},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1161/jaha.125.048737}
}
Kostenlos starten →